2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · IEX Real-Time Price · USD
4.470
-0.050 (-1.11%)
At close: Jul 19, 2024, 4:00 PM
4.610
+0.140 (3.13%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
2seventy bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 10.67, with a low estimate of 5.00 and a high estimate of 18. The average target predicts an increase of 138.70% from the current stock price of 4.47.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 2seventy bio stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +11.86% | Jun 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +146.09% | May 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +168.46% | Apr 8, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +11.86% | Mar 18, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $5 → $18 | Hold → Buy | Upgrades | $5 → $18 | +302.68% | Jan 31, 2024 |
Financial Forecast
Revenue This Year
61.16M
from 100.39M
Decreased by -39.07%
Revenue Next Year
79.10M
from 61.16M
Increased by 29.32%
EPS This Year
-2.28
from -4.42
EPS Next Year
-0.63
from -2.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 131.5M | 115.2M | 115.7M | 127.1M | 186.0M |
| Avg | 61.2M | 79.1M | 92.3M | 120.4M | 180.7M |
| Low | 34.4M | 53.3M | 62.3M | 112.7M | 173.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.0% | 88.3% | 46.3% | 37.6% | 54.5% |
| Avg | -39.1% | 29.3% | 16.7% | 30.3% | 50.1% |
| Low | -65.7% | -12.8% | -21.2% | 22.0% | 44.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.09 | 1.46 | -0.16 | 0.24 |
| Avg | -2.28 | -0.63 | -0.53 | 0.23 |
| Low | -3.21 | -1.35 | -1.33 | 0.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.